Who are Palisade Bio, Inc.'s main suppliers?

Palisade Bio, Inc. (PALI) key suppliers include: GIIANT, ITERATIVE-SCOPES-INC-D-B-A-ITERATIVE-HEALTH, WUXI-APPTEC, REGENTS-OF-THE-UNIVERSITY-OF-CALIFORNIA, Alto Neuroscience, Inc. and 4 more. View the full supplier network at chainsifter.com/chain/PALI.

Who are Palisade Bio, Inc.'s major customers?

Palisade Bio, Inc. (PALI) key customers include: NEWSOARA, Johnson & Johnson, Johnson & Johnson, ORANY, ORANY and 3 more. View the full customer network at chainsifter.com/chain/PALI.

What sector is Palisade Bio, Inc. in?

Palisade Bio, Inc. (PALI) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Palisade Bio, Inc. Supplier List (PALI): 9 Verified Suppliers

9Suppliers

8Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Palisade Bio, Inc. (PALI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

4Distinct source URLs

9High confidence

0.777Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Palisade Bio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GIIANT	GIIANT	92%	The Company has an obligation to make contingent consideration payments to Giiant, in either cash or shares of the Company’s common stock solely at the Company’s election, upon the achievement of dev…
ITERATIVE-SCOPES-INC-D-B-A-ITERATIVE-HEALTH	ITERATIVE-SCOPES-INC-D-B-A-ITERATIVE-HEALTH	90%	pursuant to which IH has agreed to, among other things, assist the Company with the Study Enrollment
WUXI-APPTEC	WUXI-APPTEC	85%	our current CMO for the manufacture and supply of API for PALI-2108
REGENTS-OF-THE-UNIVERSITY-OF-CALIFORNIA	REGENTS-OF-THE-UNIVERSITY-OF-CALIFORNIA	80%	the Company entered into three license agreements, as amended, with the Regents of the University of California
ANRO	Alto Neuroscience, Inc.	72%	Reciprocal relationship from ANRO graph: Reciprocal relationship from PALI graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from PALI graph: Reciprocal relationship from ANRO g…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PALI graph: oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Development…
JNJ	Johnson & Johnson	72%	oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Development: Design and development of stable and effective drug formulations suitable for c…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from PALI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from PALI graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Development: Design and development of stable and effective drug formulations suitable for c…

Palisade Bio, Inc. Customers

Ticker	Name	Confidence	Evidence
NEWSOARA	NEWSOARA	90%	During the three months ended March 31, 2026 and 2025, the Company recognized no license revenue from Newsoara under the Newsoara Co-Development Agreement.
JNJ	Johnson & Johnson	72%	oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Development: Design and development of stable and effective drug formulations suitable for c…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PALI graph: oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Development…
ORANY	ORANY	72%	oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Development: Design and development of stable and effective drug formulations suitable for c…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from PALI graph: oduction: High-quality synthesis of active ingredients under stringent regulatory standards. • Formulation Developme…
GIIANT-PHARMA-INC	GIIANT-PHARMA-INC	62%	s its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment. Contingent Consideration Ob…
LEADING-BIOSCIENCES-INC	LEADING-BIOSCIENCES-INC	62%	be no assurance that our product candidates will obtain regulatory approval. • If clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108. • It …
SENECA-BIOPHARMA-INC	SENECA-BIOPHARMA-INC	62%	be no assurance that our product candidates will obtain regulatory approval. • If clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108. • It …

Palisade Bio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PALI-DEBT-11651	Warrants outstanding: 644138	90%	xbrl warrant detail from xbrl 2026-03-31.
PALI-DEBT-11652	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2014-12-31.
PALI-DEBT	Debt stack $87,000	90%	Market cache reports total debt of $87,000.

Palisade Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Palisade Bio, Inc..

Palisade Bio, Inc. Ownership

Holder	Name	Confidence	Evidence
PALI-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 98 tracked holders.

Palisade Bio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
JNJ	Johnson & Johnson	100.00	1	['customer', 'supplier']
SNYNF	Sanofi	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
AVTX	Avalo Therapeutics, Inc.	100.00	2
BLTE	Belite Bio, Inc	50.00	2
CVRX	CVRx, Inc.	50.00	2
AUMN	Golden Minerals Company	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
AMZE	Amaze Holdings, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
AORT	Artivion, Inc.	50.00	2
AVBP	ArriVent BioPharma, Inc.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
ANIK	Anika Therapeutics, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
CHUC	Charlie's Holdings, Inc.	50.00	2
CLNE	Clean Energy Fuels Corp.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2

Palisade Bio, Inc. Supply Chain